Compounded GLP-1 and GIP/GLP-1 are not approved by the FDA and have not been evaluated for safety, effectiveness, or quality by the FDA
These treatments did not obviously alter the food intake or body weight of the rats throughout the treatment period (Figure 1)
Several studies have shown that ketogenic diets significantly reduce hunger and food intake, likely due to the increased production of ketone bodies, stable glycemia and altered levels of appetite-regulating hormones
This is when the micronutrient support matters most long-term GLP-1 use is associated with progressive nutrient depletion (Urbina 2026), and consistent replenishment is the countermeasure.*
The medication supports the work, but its not the whole treatment
Second, issues related to the route of administration and biodistribution remain unresolved, highlighting the need for precise targeting strategies or localized delivery to increase therapeutic efficacy